知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.027 seconds)

    Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
    4.
    发明授权
    Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof 失效
    在人血清，抗体中发现的二肽基肽酶IV（CD26）的形式及其用途

    公开(公告)号：US06265551B1

    公开(公告)日：2001-07-24

    申请号：US08657339

    申请日：1996-06-03

    Applicant: Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

    Inventor： Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

    IPC: C07K1600

    CPC classification number: G01N33/573 ,  A61K38/00 ,  C07K16/40 ,  C12N9/48 ,  Y10S435/975

    Abstract: A circulating, soluble form of DPPIV/CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the ubiquitous membrane form. However, in several biochemical aspects there are distinct differences. In particular, the circulating serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the circulating form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Circulating DPPIV has been determined to be the soluble form of a 175 kDa DPPIV CD26-related molecule rapidly expressed on the surface of activated T cells, prior to the expression of 105 kDa CD26. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from 105 kDa CD26/DPPIV. Polyclonal and monoclonal antibodies capable of distinguishing the 175 kDa form from the 105 kDa form are also disclosed.

    Abstract translation: 公开了从人血清中分离的循环的可溶形式的DPPIV / CD26。 血清形式与普遍存在的膜形式具有相似的酶和抗原性质。 然而，在几个生化方面有明显的差异。 特别地，循环血清形式的分子量为175kDa（与膜形式的105kDa分子量相反），并且不结合腺苷脱氨酶1型。 然而，循环形式表达功能性二肽基肽酶IV活性，并保留共同刺激T淋巴细胞回忆抗原的能力。 循环DPPIV已被确定为在表达105kDa CD26之前在激活的T细胞表面上快速表达的175kDa DPPIV CD26相关分子的可溶形式。 尽管可以少量在血清中发现105kDa膜型CD26，但大部分血清DPPIV活性由与105kDa CD26 / DPPIV结构不同的新型肽酶提供。 还公开了能够区分175kDa形式与105kDa形式的多克隆和单克隆抗体。

    Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
    7.
    发明授权
    Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof 失效
    鉴定免疫调节剂，免疫调节剂及其用途的方法

    公开(公告)号：US07704686B2

    公开(公告)日：2010-04-27

    申请号：US10584837

    申请日：2004-12-28

    Applicant: Chikao Morimoto ,  Kei Ohnuma

    Inventor： Chikao Morimoto ,  Kei Ohnuma

    IPC: A61K48/00

    CPC classification number: C12N15/113 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/505 ,  G01N33/9493

    Abstract: The present invention provides methods of identifying a substance that down-regulates or up-regulates an immune response and kits used for the identification methods. A method of this invention comprises detecting a substance that inhibits or enhances the interaction between CD26 and caveolin-1. Another method comprises detecting a substance that inhibits or enhances the interaction between caveolin-1 and Tollip. Still another method comprises detecting a substance that inhibits or enhances the interaction among caveolin-1, Tollip, and IRAK-1. The present invention also relates to immunoregulatory agents comprising a substance that down-regulates an immune response, such as siRNA against caveolin-1 or Tollip. The invention further provides immunoregulatory agents comprising a substance that up-regulates an immune response. These agents are useful for treating inflammatory diseases, autoimmune diseases, or other immune-mediated disorders.

    Abstract translation: 本发明提供鉴定下调或上调免疫应答的物质的方法和用于鉴定方法的试剂盒的方法。 本发明的方法包括检测抑制或增强CD26和小窝蛋白-1之间相互作用的物质。 另一种方法包括检测抑制或增强窖1与Tollip之间相互作用的物质。 另一种方法包括检测抑制或增强窖1，Tollip和IRAK-1之间相互作用的物质。 本发明还涉及免疫调节剂，其包含下调免疫应答的物质，例如针对窖1或Tollip的siRNA。 本发明进一步提供了包含上调免疫应答的物质的免疫调节剂。 这些药剂可用于治疗炎性疾病，自身免疫疾病或其他免疫介导的疾病。

Patent Agency Ranking